Keyphrases
Adverse Drug Reaction
85%
Lactancia Materna
42%
Safety Patterns
42%
Therapeutic Consultations
42%
Hip Fracture Surgery
42%
Hospital Registry
42%
Lymphopenia
42%
COVID-19
42%
Registry Study
42%
Drug Use
42%
Close Monitoring
42%
Drug Safety
42%
Siponimod
42%
Retrospective Cohort Study
42%
Adverse Effects
42%
Multiple Sclerosis
42%
Biological Agents
42%
Disease-modifying Therapy
42%
Safety Aspects
42%
Usage Patterns
42%
Treatment Issues
42%
Pharmacological Treatment
42%
Perioperative Management
42%
Outpatient Treatment
42%
Medication-related Problems
42%
Severe Disease
42%
Thrombotic
42%
Nursing Homes
42%
Multidisciplinary Approach
42%
Hospital Outpatient Clinics
42%
Aspirin
42%
Patient Register
42%
Catalonia
42%
Off-label Use
40%
Clinical Practice
40%
Agent Selection
28%
Teratogenic Potential
28%
Enfermedad
28%
American College of Chest Physicians
28%
Thromboembolic Risk
28%
After Surgery
28%
Bridging Therapy
28%
Enoxaparin
28%
Seguridad
21%
Health Professionals
20%
Polypharmacy
18%
Institutionalized Patients
18%
Clinical Trials
18%
Protein Antagonist
14%
Fusion Cytokine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Adverse Drug Reaction
80%
Retrospective Study
57%
Observational Study
42%
Cohort Study
42%
Lymphocytopenia
42%
Anticoagulant Agent
42%
Polypharmacy
42%
Hip Fracture
42%
Coronavirinae
42%
Siponimod
42%
Biological Product
42%
Adverse Event
42%
Hypercholesterolemia
42%
Proprotein Convertase 9
42%
Alirocumab
42%
Evolocumab
42%
Cardiovascular Risk
42%
Off-Label Use
39%
Clinical Trial
38%
Chronic Disease
28%
Acetylsalicylic Acid
25%
Thromboembolism
22%
Enoxaparin
17%
Cytokine Receptor Antagonist
14%
Drug-Drug Interaction
14%
Prevalence
14%
Frailty
14%
Cross-Sectional Study
14%
Multiple Chronic Conditions
14%
Autoimmune Disease
14%
Etanercept
14%
Monoclonal Antibody
14%
Infliximab
14%
Adalimumab
14%
Rituximab
14%
Chimeric Protein
14%
Familial Hypercholesterolemia
14%
Cardiovascular Disease
14%
Diarrhea
10%
Acenocoumarol
8%
Bleeding
8%
Clopidogrel
8%
Triflusal
8%
Disease Predisposition
6%
Pharmacovigilance
5%
Thrombocytopenia
5%
Chronic Kidney Failure
5%
Lenalidomide
5%
Infection
5%
Medicine and Dentistry
Drug Therapy
48%
COVID-19
42%
Siponimod
42%
Nursing Home
42%
Adverse Drug Reaction
42%
Observational Study
42%
Retrospective Cohort Study
42%
Hip Fracture
42%
Antithrombotic
42%
Lymphocytopenia
42%
Acetylsalicylic Acid
25%
Clinical Trial
24%
Diseases
18%
Thromboembolism
17%
Off-Label Use
12%
Polypharmacy
11%
Anesthesiology
8%
Triflusal
8%
Bleeding
8%
Clopidogrel
8%
Acenocoumarol
8%
Chronic Disease
7%
Sequela
6%
Patient Registry
6%
Infection
6%
Hydroxychloroquine
6%
Fatality
6%
Disease Predisposition
6%
Lopinavir/Ritonavir
6%
Azithromycin
6%
Lymphocyte
6%
Medical Record
6%
